

Hansa Biopharma AB (HNSA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/H4B29D7BEF0EN.html>

Date: May 2021

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: H4B29D7BEF0EN

Abstracts

Hansa Biopharma AB (HNSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hansa Biopharma AB (Hansa Biopharma) focuses on the development of novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company's lead project, imlifidase is a proprietary antibody cleaving enzyme for kidney transplant patients. Its preclinical assets include NiceR for recurring treatment in autoimmune disease, transplantation and cancer; and EnzE, cancer immunotherapy. Hansa Biopharma offers a novel diagnostic method HBP-assay (serum quantification of Heparin Binding Protein) to help predict severe sepsis in patients with infectious disease symptoms. The company has out-licensed its HBP-assay (serum quantification of Heparin-Binding Protein), a novel diagnostic method to help predict severe sepsis in patients with infectious disease symptoms to Axis-Shield Diagnostics. Hansa Biopharma is headquartered in Lund, Sweden.

Hansa Biopharma AB Key Recent Developments

Apr 22,2021: Hansa Biopharma interim report Jan-Mar 2021

Apr 14,2021: Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update

Apr 08,2021: Hansa Biopharma publishes Annual Report 2020

Mar 01,2021: Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development

Feb 04,2021: Hansa Biopharma year-end report Jan-Dec 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Hansa Biopharma AB - Key Facts
Hansa Biopharma AB - Key Employees
Hansa Biopharma AB - Key Employee Biographies
Hansa Biopharma AB - Major Products and Services
Hansa Biopharma AB - History
Hansa Biopharma AB - Company Statement
Hansa Biopharma AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Hansa Biopharma AB - Business Description
R&D Overview
Hansa Biopharma AB - Corporate Strategy
Hansa Biopharma AB - SWOT Analysis
SWOT Analysis - Overview
Hansa Biopharma AB - Strengths
Hansa Biopharma AB - Weaknesses
Hansa Biopharma AB - Opportunities
Hansa Biopharma AB - Threats
Hansa Biopharma AB - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Hansa Biopharma AB, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 14, 2021: Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update

Apr 08, 2021: Hansa Biopharma publishes Annual Report 2020

Mar 01, 2021: Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development

Feb 04, 2021: Hansa Biopharma year-end report Jan-Dec 2020

Jan 11, 2021: Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference

Oct 22, 2020: Hansa Biopharma interim report Jan-Sep 2020

Sep 01, 2020: Hansa Biopharma provides updated guidance on its clinical programs

Jul 16, 2020: Hansa Biopharma interim report Jan-Jun 2020

Jul 16, 2020: Hansa Biopharma expands the leadership team with the appointment of Katja Margell as new Head of Corporate Communications

Jun 30, 2020: Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Half of 2020 and Business Update

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Hansa Biopharma AB, Key Facts
Hansa Biopharma AB, Key Employees
Hansa Biopharma AB, Key Employee Biographies
Hansa Biopharma AB, Major Products and Services
Hansa Biopharma AB, History
Hansa Biopharma AB, Subsidiaries
Hansa Biopharma AB, Key Competitors
Hansa Biopharma AB, Ratios based on current share price
Hansa Biopharma AB, Annual Ratios
Hansa Biopharma AB, Annual Ratios (Cont...1)
Hansa Biopharma AB, Interim Ratios
Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hansa Biopharma AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Hansa Biopharma AB, Performance Chart (2016 - 2020)

Hansa Biopharma AB, Ratio Charts

Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Hansa Biopharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Hansa Biopharma AB (HNSA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/H4B29D7BEF0EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H4B29D7BEF0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970